This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Novo Holdings-Catalent deal could negatively impact pharma companies, Eli Lilly tells Brazilian regulator

By Flavia Fortes ( August 26, 2024, 18:02 GMT | Insight) -- Eli Lilly told the Brazilian competition authority that the acquisition of Catalent by Novo Holdings could impact pharmaceutical companies that depend on the drug manufacturer’s services. Although most of the American drugmaker’s responses were confidential, Eli Lilly said the deal could confer competitive advantages on Novo and result in shortages of contract development and manufacturing organization services that are essential to other drug manufacturers.Eli Lilly told the Brazilian competition authority that the acquisition of Catalent by Novo Holdings could impact pharmaceutical companies that depend on the drug manufacturer’s services....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login